Andrew Brack

The next OpenADMET blind challenge is about to launch. This one is will predict Pregnane-X Receptor (PXR) induction. PXR is a nuclear hormone receptor and master regulator of drug-metabolizing enzymes and transporters. This challenge comes with a PXR dataset of more than *11,000* compounds sourced from two Enamine libraries (Discovery Diversity 10 set and FDA Approved Drugs set) profiled through a rigorous multi-step assay flow reminiscent of an on-target drug discovery program.

The Alliance for Longevity Initiatives (A4LI) would like to applaud the passage of HB1734 and HB1735 in the New Hampshire House of Representatives, two groundbreaking pieces of legislation designed to expand patient access to cutting-edge medical treatments and accelerate the development of next-generation therapies. Together, these bills represent a major step toward making New Hampshire a national leader in biomedical innovation and patient access to promising therapies. The legislation builds on reforms A4LI advocated for in Montana, where policymakers previously enacted similar policies designed to expand access to experimental therapies while encouraging biomedical innovation. We look forward to keeping you all updated as both pieces of legislation now advance to the New Hampshire Senate for consideration.

This is what I've been building with my body. Prompt (.md): Don't Die Agent iterates on (.py): protocol Validation loss: 1,000's of biomarkers Goal: remove the impulsive human from the loop to achieve autonomous biological vitality.